Your Medications Aren't Working or You're Having Strange Side Effects. Your Genes May Be Why.

CYP2D6 is one of the most important drug-metabolizing enzymes in your liver. It handles roughly one-quarter of all medications you’re likely to take in your lifetime. This includes antidepressants (sertraline, paroxetine, venlafaxine), opioid painkillers (codeine, tramadol, metoprolol), beta-blockers used for heart disease and anxiety, and many antihistamines.

If you carry the *4, *10, or *17 variant, your CYP2D6 enzyme works much more slowly than normal. Roughly 7-10% of people of European ancestry are poor metabolizers for this gene. When you’re a poor metabolizer, drugs that rely on CYP2D6 to be broken down simply sit in your bloodstream longer. The half-life of the drug extends. Doses accumulate. You experience side effects at doses that should be therapeutic.

This is especially dangerous with opioids and antidepressants. Codeine doesn’t work because your body can’t convert it to its active form, morphine. Sertraline or paroxetine causes nausea, tremors, sexual dysfunction, or insomnia at standard doses because the drug is accumulating faster than your body can clear it. Beta-blockers cause fatigue or low blood pressure that seems disproportionate to the dose. You feel trapped between no effect and intolerable side effects.

CYP2C19 handles some of the most important medications in modern medicine, including clopidogrel (Plavix), a blood thinner that prevents stent thrombosis and heart attacks in millions of people. It also metabolizes proton pump inhibitors like omeprazole used for reflux, and multiple antidepressants including escitalopram and sertraline.

If you carry the *2 or *3 poor metabolizer variant, your CYP2C19 enzyme is severely impaired. Poor metabolizers represent 2-15% of the population depending on your ancestry, with higher rates in Asian populations. Here’s where it gets critical: clopidogrel is a prodrug, meaning your body has to convert it into its active form to prevent blood clots. If you’re a poor metabolizer and you’re taking clopidogrel after a stent placement, your body may not be activating it. You get zero antiplatelet benefit. The stent can clot. You can have a heart attack.

For antidepressants and PPIs, poor metabolizers experience similar accumulation: higher blood levels, more side effects, less predictable response. You take omeprazole for acid reflux but feel no relief, or you take escitalopram and experience tremors and sleep disruption at a standard dose.

CYP2C9 metabolizes warfarin, the oral anticoagulant that hundreds of thousands of people take daily to prevent blood clots. It also breaks down ibuprofen, naproxen, meloxicam, and other NSAIDs, plus some statins. Warfarin is one of the oldest and most effective anticoagulants, but it has a razor-thin therapeutic window. Too little and you get a clot. Too much and you bleed internally.

If you carry the *2 or *3 variant, your CYP2C9 enzyme is slow. Roughly 5-10% of people of European ancestry are poor metabolizers for CYP2C9. When you’re a poor metabolizer taking warfarin at a standard dose, the drug accumulates faster than you can clear it. Your INR (a measure of blood thinning) climbs higher than intended. You become over-anticoagulated. You bleed from your gums, bruise from minor bumps, have blood in your urine, or experience gastrointestinal bleeding.

The tragedy is that this is entirely preventable. Your doctor can safely prescribe warfarin to poor metabolizers, but the dose must be 20-40% lower than the standard starting dose. Without genetic testing, your doctor has no way to know this. You end up hospitalized with bleeding complications that never should have happened.

VKORC1 doesn’t metabolize warfarin. Instead, it encodes the target protein that warfarin blocks. Warfarin works by inhibiting VKORC1, which prevents your body from recycling vitamin K. This disrupts the production of clotting factors and prevents blood clots. If your VKORC1 has certain variants, you’re inherently more sensitive to warfarin. Your body recycles vitamin K less efficiently, so blocking it has a bigger effect.

The -1639G>A variant in VKORC1 is extremely common. Roughly 40% of people of European ancestry carry the A allele, which makes them more sensitive to warfarin. If you have this variant, a standard warfarin dose pushes you into over-anticoagulation territory faster. You bleed at lower doses than people without the variant. Your INR swings wildly with small dose changes.

The practical consequence is that you need a lower starting dose and more careful monitoring. Without genetic testing, your doctor assumes you’re average. They start you on the standard dose. Your INR shoots up. You experience bleeding or near-bleeding events before your doctor realizes you need a lower dose. With testing, you start at the right dose from day one.

SLCO1B1 encodes a transporter protein that pumps statins into liver cells. Statins work inside liver cells, so if the transporter doesn’t work well, statins stay in your bloodstream instead of getting to where they’re needed. The *5 variant reduces this transporter’s function. People with the *5 variant have higher statin levels in their blood and lower levels inside their liver cells.

The SLCO1B1 *5 variant (rs4149056) is moderately common, carried by roughly 15% of the population. If you have this variant and you’re taking simvastatin or atorvastatin, statin levels in your blood are 2-3 times higher than they should be. You experience muscle pain, weakness, or breakdown (myopathy) at doses that are supposed to be safe. Your doctor thinks you’re statin-intolerant. You’ve been told to stop statins or take a lower dose. But the problem isn’t statins in general; it’s that these specific statins don’t get into your liver efficiently.

This variant is particularly important for people taking high-dose simvastatin, which is notorious for causing muscle problems. You take a standard dose and within weeks you have unexplained muscle pain or weakness. Blood tests may or may not show elevated creatine kinase. Your doctor blames the statin and tells you to stop. But alternative statins like pravastatin or rosuvastatin, which don’t rely on SLCO1B1, work fine for you.

TPMT metabolizes thiopurine drugs, which are used to treat autoimmune conditions like rheumatoid arthritis, lupus, inflammatory bowel disease, and some cancers. These are powerful immune-suppressing medications. Your body needs to metabolize them carefully so they suppress your immune system without destroying your bone marrow and causing life-threatening anemia or infection.

If you carry a poor metabolizer variant in TPMT, your body cannot break down thiopurines efficiently. Roughly 0.3% of the population, or about 1 in 300 people, are poor metabolizers for TPMT. When a poor metabolizer takes a standard dose of azathioprine or 6-mercaptopurine, the drug accumulates in your body. You experience severe bone marrow suppression, meaning your white blood cell and platelet counts plummet. You become vulnerable to life-threatening infections. Your blood clotting fails. You hemorrhage internally.

This is not a rare side effect that happens to some people. If you’re a poor metabolizer and you take a standard dose, this is an expected outcome. Yet TPMT testing is not universal. Many people with autoimmune conditions start these medications without ever being tested. They experience mysterious bone marrow suppression and are told it’s an idiosyncratic reaction or bad luck. The truth is your genes predicted this from the start.